Skip to main content
Pulike Biological Engineering,Inc. logo

Pulike Biological Engineering,Inc. — Investor Relations & Filings

Ticker · 603566 ISIN · CNE1000025N0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,080 across all filing types
Latest filing 2015-05-21 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 603566

About Pulike Biological Engineering,Inc.

http://en.pulike.com.cn/

Pulike Biological Engineering, Inc. specializes in the research, development, and production of veterinary biological products and pharmaceutical preparations. The company focuses on animal disease prevention through the manufacture of high-end vaccines, diagnostic reagents, and veterinary medicines. Its product range primarily serves the swine and poultry sectors, featuring advanced biologicals such as genetically engineered vaccines and synthetic peptide products. Pulike maintains a strong emphasis on technological innovation, utilizing national-level research platforms to develop solutions for complex animal health challenges. The company’s core activities encompass the entire value chain from basic biotechnology research to the commercialization of veterinary health solutions, aiming to improve livestock productivity and biosecurity.

Recent filings

Filing Released Lang Actions
关于回复生物工程股份有限公司了解股票异常波动有关情况的函
Regulatory Filings
2015-05-21 Chinese
股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is a short announcement regarding abnormal stock price fluctuations over three consecutive trading days, with the company confirming no undisclosed material information. It references stock trading rules and provides a risk warning to investors. The document length is only 1032 characters, indicating it is a brief regulatory announcement rather than a full financial report or detailed filing. There is no financial data, no management discussion, no voting results, no audit information, or other report content. This fits the category of a Regulatory Filing (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2015-05-21 Chinese
公司章程
Regulatory Filings
2015-05-14 Chinese
首次公开发行股票上市公告书
Regulatory Filings Classification · 95% confidence The document is titled "上市公告书" which translates to "Listing Announcement" or "IPO Listing Announcement". It details the company's initial public offering (IPO) including stock code, stock abbreviation, issuance price, number of shares issued, lock-up commitments by shareholders, stock price stabilization measures, underwriting and sponsorship information, and regulatory approvals. It also includes financial data such as audited financial reports and first quarter unaudited financial data, but these are summarized and not the full financial report. The document is a formal announcement related to the company's IPO and stock listing on the Shanghai Stock Exchange. It is not an annual report, earnings release, or other financial report. It is a regulatory announcement about the company's stock listing and IPO details. Therefore, it fits best into the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories. The document is lengthy (15,000 characters) and contains detailed information about the IPO listing, but it is not a financial report itself. Hence, the classification is RNS with high confidence.
2015-05-14 Chinese
首次公开发行股票网上按市值申购定价发行摇号中签结果公告
Share Issue/Capital Change Classification · 100% confidence The document is an announcement of lottery results for the allocation of shares in an initial public offering (IPO) of 普莱柯生物工程股份有限公司. It details the winning numbers for the share subscription lottery and the process of the lottery event. This is not a financial report, earnings release, or management discussion. It is a capital market event related to share issuance and allocation. Therefore, it fits best under the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues and related capital changes. The document is short and focused solely on the lottery results for IPO share allocation, confirming the classification.
2015-05-11 Chinese
首次公开发行股票网下发行结果及网上中签率公告
Capital/Financing Update Classification · 95% confidence The document is titled as an announcement of the results of the offline issuance and the online winning rate for the initial public offering (IPO) of shares by 普莱柯生物工程股份有限公司. It details the allocation results of shares to investors, subscription amounts, and the final winning rates for the online issuance. It references regulatory approval from the China Securities Regulatory Commission and includes detailed tables of investors and their allocations. The document is focused on the issuance and allocation of shares in an IPO, which is a capital raising event. It does not contain financial statements or management discussion but is an update on the capital issuance process and results. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed allocation data, supporting a high confidence in this classification.
2015-05-10 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.